PYXSPyxis Oncology, Inc.同业对比
Pyxis Oncology, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PYXS本股 | $138M#3 | — | 12.0x#7 | 9.9x#3 | -14.2%#6 | -3.0%#7 | -609.2%#4 | -696.0%#8 | — | — | -57.7%#7 | — |
| RNA | $149M#1 | — | 0.7x#2 | — | — | — | — | 0.0%#1 | — | — | — | — |
| KRSA | $142M#2 | — | 27.9x#8 | 68.4x#4 | 3.7%#4 | -15.4%#8 | -239.8%#2 | -69.4%#5 | -69.1%#1 | — | 147.5%#1 | — |
| CUE | $134M#4 | — | 57.8x#9 | 4.9x#2 | 195.7%#2 | 34.6%#1 | -96.7%#1 | -1151.6%#9 | — | — | -15.8%#4 | — |
| SCNX | $131M#5 | — | 2.0x#5 | 303.5x#5 | 215.9%#1 | -404.5%#9 | -9867.9%#6 | -64.8%#4 | -73.5%#2 | 4#1 | -79.8%#8 | 11.3%#1 |
| SPRB | $130M#6 | — | 1.6x#4 | — | -100.0%#7 | 26.5%#2 | — | -46.5%#3 | — | — | -56.4%#6 | — |
| FHTX | $125M#7 | — | — | 4.0x#1 | 36.8%#3 | 14.2%#4 | -279.5%#3 | — | — | — | — | — |
| ZNTL | $125M#8 | — | 0.9x#3 | — | -100.0%#7 | 17.4%#3 | — | -95.4%#7 | — | — | 32.8%#2 | — |
| NKTX | $124M#9 | — | 0.5x#1 | — | — | 4.3%#6 | — | -42.0%#2 | — | — | -12.2%#3 | — |
| NERV | $122M#10 | — | — | — | — | -20492.7%#10 | — | — | — | — | -30.8%#5 | — |
| ANIX | $114M#11 | — | 7.9x#6 | 541.3x#6 | 0.0%#5 | 13.0%#5 | -5571.9%#5 | -75.5%#6 | -87.0%#3 | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-04。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议